Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

avimedical b.v. - enrofloxacin - oral solution - 25 milligram(s)/millilitre - enrofloxacin - other birds, rabbits, reptiles, rodents - antibacterial

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

elanco gmbh - enrofloxacin - solution for injection - 25 milligram(s)/millilitre - enrofloxacin

Amerika Serikat - Inggris - NLM (National Library of Medicine)

dechra vet products, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. contraindications: enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Spanyol - Inggris - HMA (Heads of Medicines Agencies)

s.p. veterinaria s.a - enrofloxacin 5 mg/ml - oral solution - pigs food - enrofloxacin

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) - enrofloxacin 5 mg in 1 ml - baytril® otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see microbiology section). baytril® otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides.

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

le vet bv - enrofloxacin - tablet - 15 mg/tablet - enrofloxacin - cats, dogs - antibacterial

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

Amerika Serikat - Inggris - NLM (National Library of Medicine)

putney, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg in 1 ml

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

emdoka bvba - enrofloxacin - solution for injection - 25 milligram(s)/millilitre - enrofloxacin